Haemonetics Corporation (HAE) Revenue-to-Profit Sankey Flow & SEC XBRL Financials
Haemonetics Corporation (HAE) carries a Roarable Rating of C+ (Hold) with 68/100 RQD Confidence. The underlying business is intact, so current owners don’t need to panic-sell—but mixed big-money flow or rich pricing means new buyers can afford to wait for either a pullback or a B-or-higher upgrade.
How HAE Turns Every Dollar of Sales Into Real Bottom-Line Profit
Multi-Year SEC EDGAR XBRL Revenue, Net Profit & Free Cash Flow Trajectory
| Fiscal Year | Revenue | Gross Margin | Op Margin | Net Profit | Free Cash Flow | ROIC % |
|---|---|---|---|---|---|---|
| FY 2025 | $1.33B | 59% | 11.7% | $97.3K | $260.4M | 8.4% |
| FY 2024 | $1.36B | 55% | 16.3% | $167.7K | $142.4M | 9.7% |
| FY 2023 | $1.31B | 44% | 12.6% | $117.6M | $122.8M | 7.2% |
Red-Light Warning Desk: How Pros Profit When Overhyped Stocks Crack (Featuring HAE)
- ✓Live walkthrough of HAE's RQD Radar, SEC cash-conversion gap & downside levels
- ✓3 asymmetric Bear/Hedge setups institutions use when 10-year yields stay elevated
- ✓Includes instant 24/7 email alert whenever any of your stocks flip to Red
HAE Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
vs. -2.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
No active Ellis Vennor swing setup published on HAE today. View full Setup Ledger →
No direct multi-tier Butterfly edges indexed yet for HAE. Explore sector supply chains on /butterfly.
HAE Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDHow profitable is Haemonetics Corporation (HAE)?
In FY 2025 (10-K), HAE converted $1.3B of revenue into a 59% gross margin, 11.7% operating margin, and $260.4M in free cash flow (19.5% FCF margin).